Skip to Content

Foscavir (foscarnet) Disease Interactions

There are 4 disease interactions with Foscavir (foscarnet):

Major

Foscarnet (Includes Foscavir) ↔ Dehydration

Severe Potential Hazard, High plausibility

Applies to: Dehydration

Foscarnet is nephrotoxic. Foscarnet crystals may deposit in renal tubules and capillaries, sometimes causing acute tubular necrosis and renal failure. Foscarnet may also concentrate in the urine and cause penile or vulvovaginal irritation. Adequate hydration is crucial to minimize the risk of renal damage and genital ulcerations. Generally, foscarnet should be administered by an infusion pump over 1 to 2 hours accompanied by hydration. The manufacturer recommends 750 to 1000 mL of normal saline or 5% dextrose solution prior to the first infusion of foscarnet to establish diuresis, then 500 mL (for 40 to 60 mg/kg dose of foscarnet) or 750 to 1000mL (for 90 to 120 mg/kg dose of foscarnet) of hydration fluid concurrently with each subsequent foscarnet infusion. Patients who are dehydrated may be at increased risk for the development of nephrotoxicity and may benefit from additional hydration if tolerated.

References

  1. Evans LM, Grossman ME "Foscarnet-induced penile ulcer." J Am Acad Dermatol 27 (1992): 124-6
  2. Deray G, Le Hoang P, Soubrie C, et al "Foscarnet-induced acute renal failure and effectiveness of haemodialysis." Lancet 2 (1987): 216
  3. Sohl Akerlund A, Keisu M, Lernestedt JO, Sandberg M "Penile ulcerations in connection with foscarnet therapy. Clinical picture and incidence." Int Conf AIDS 9 (1993): 358
  4. "Product Information. Foscavir (foscarnet)." Astra USA, Westborough, MA.
  5. Chrisp P, Clissold SP "Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis." Drugs 41 (1991): 104-29
  6. Cacoub P, Deray G, Baumelou A, et al "Acute renal failure induced by foscarnet: 4 cases." Clin Nephrol 29 (1988): 315-8
  7. Caumes E, Gatineau M, Bricaire F, Dohin E, Katlama C, Gentilini M "Foscarnet-induced vulvar erosion." J Am Acad Dermatol 28 (1993): 799
  8. Moyle G, Barton S, Gazzard BG "Penile ulceration with foscarnet therapy." AIDS 7 (1993): 140-1
  9. Deray G, Martinez F, Katlama C, et al "Foscarnet nephrotoxicity: mechanism, incidence and prevention." Am J Nephrol 9 (1989): 316-21
  10. Navarro JF, Quereda C, Moreno A, Quereda C "Renal tubular acidosis following treatment with foscarnet." AIDS 9 (1995): 1389-90
  11. Gilquin J, Weiss L, Kazatchkine MD "Genital and oral erosions induced by foscarnet." Lancet 335 (1990): 287
  12. Saint-Marc T, Fournier F, Touraine J-L, Marneff E "Uvula and oesophageal ulcerations with foscarnet." Lancet 340 (1992): 970-1
  13. Deray G, Katlama C, Dohin E "Prevention of foscarnet nephrotoxicity." Ann Intern Med 113 (1990): 332
  14. Fegeuex S, Salmon D, Picard C, et al "Penile ulcerations with foscarnet." Lancet 335 (1990): 547-8
  15. Jacobson MA "Review of the toxicities of foscarnet." J Acquir Immune Defic Syndr 5 (1992): s11-7
  16. Lacey HB, Ness A, Mandal BK "Vulval ulceration associated with foscarnet." Genitourin Med 68 (1992): 182
  17. Holbrook J, Jabs D, Jacobson M, Mendez P, Min Y, Murphy R "Foscarnet-related abnormalities in serum creatinine, calcium, and magnesium in patients with CMV retinitis. The SOCA Research Group." Int Conf AIDS 9 (1993): 361
View all 17 references
Major

Foscarnet (Includes Foscavir) ↔ Electrolyte Disturbances

Severe Potential Hazard, High plausibility

Applies to: Hypocalcemia, Hypokalemia, Magnesium Imbalance, Phosphate Imbalance, Electrolyte Abnormalities, CNS Disorder, Heart Disease

Foscarnet may cause electrolyte disturbances, including hypocalcemia, hypo- or hyperphosphatemia, hypomagnesemia, and hypokalemia. Ionized serum calcium may also demonstrate a dose-dependent (and possibly rate-dependent) decrease that may not be reflected in total serum calcium. Patients should be instructed to report symptoms of low ionized calcium such as perioral tingling, numbness in the extremities, and paresthesias. Other electrolyte-related complications include tetany, seizures, and cardiac disturbances. Therapy with foscarnet should be administered cautiously in patients with preexisting fluid and electrolyte imbalance and those with underlying cardiac or neurologic abnormalities. Serum electrolyte levels should be closely monitored and managed in all patients treated with foscarnet.

References

  1. Conn J, Colman P, Brown G, Street A, Bate K "Nephrogenic diabetes insipidus associated with foscarnet - a case report." J Antimicrob Chemother 37 (1996): 1179-81
  2. Jacobson MA, Gambertoglio JG, Aweeka FT, et al "Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism." J Clin Endocrinol Metab 72 (1991): 1130-5
  3. Chrisp P, Clissold SP "Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis." Drugs 41 (1991): 104-29
  4. Malin A, Miller RF "Foscarnet-induced hypokalaemia." J Infect 25 (1992): 329-30
  5. "Product Information. Foscavir (foscarnet)." Astra USA, Westborough, MA.
  6. Jacobson MA "Review of the toxicities of foscarnet." J Acquir Immune Defic Syndr 5 (1992): s11-7
  7. Gearhart MO, Sorg TB "Foscarnet-induced severe hypomagnesemia and other electrolyte disorders." Ann Pharmacother 27 (1993): 285-9
  8. Brown DL, Sather S, Cheitlin MD "Reversible cardiac dysfunction associated with foscarnet therapy for cytomegalovirus esophagitis in an AIDS patient." Am Heart J 125 (1993): 1439-41
  9. Blanshard C "Treatment of HIV-related cytomegalovirus disease of the gastrointestinal tract with foscarnet." J Acquir Immune Defic Syndr 5 (1992): s25-8
  10. Holbrook J, Jabs D, Jacobson M, Mendez P, Min Y, Murphy R "Foscarnet-related abnormalities in serum creatinine, calcium, and magnesium in patients with CMV retinitis. The SOCA Research Group." Int Conf AIDS 9 (1993): 361
  11. Palestine AG, Polis MA, De Smet MD, et al "A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS." Ann Intern Med 115 (1991): 665-73
  12. Ringden O, Lonnqvist B, Paulin T, et al "Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients." J Antimicrob Chemother 17 (1986): 373-87
View all 12 references
Major

Foscarnet (Includes Foscavir) ↔ Renal Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Foscarnet is eliminated primarily by the kidney. Patients with renal impairment may be at greater risk for dose-limiting nephrotoxicity and other adverse effects of foscarnet due to decreased drug clearance. Renal function should be closely monitored in all patients receiving therapy with foscarnet, and the dosage adjusted based on serum creatinine. Hydration is recommended to reduce the risk of nephrotoxicity. The manufacturer recommends 750 to 1000 mL of normal saline or 5% dextrose solution prior to the first infusion of foscarnet to establish diuresis, then 500 mL (for 40 to 60 mg/kg dose of foscarnet) or 750 to 1000mL (for 90 to 120 mg/kg dose of foscarnet) of hydration fluid concurrently with each subsequent foscarnet infusion. The use of foscarnet is not recommended in patients with severe renal impairment indicated by a CrCl < 0.4 mL/min/kg.

References

  1. Cacoub P, Deray G, Baumelou A, et al "Acute renal failure induced by foscarnet: 4 cases." Clin Nephrol 29 (1988): 315-8
  2. Chrisp P, Clissold SP "Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis." Drugs 41 (1991): 104-29
  3. Deray G, Martinez F, Katlama C, et al "Foscarnet nephrotoxicity: mechanism, incidence and prevention." Am J Nephrol 9 (1989): 316-21
  4. SOCA Reseach Group, et al "Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis." N Engl J Med 326 (1992): 213-20
  5. Seidel EA, Koenig S, Polis MA "A dose escalation study to determine the toxicity and maximally tolerated dose of foscarnet." AIDS 7 (1993): 941-5
  6. MacGregor RR, Graziani AL, Weiss R, et al "Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring." J Infect Dis 164 (1991): 785-7
  7. Navarro JF, Quereda C, Moreno A, Quereda C "Renal tubular acidosis following treatment with foscarnet." AIDS 9 (1995): 1389-90
  8. Holbrook J, Jabs D, Jacobson M, Mendez P, Min Y, Murphy R "Foscarnet-related abnormalities in serum creatinine, calcium, and magnesium in patients with CMV retinitis. The SOCA Research Group." Int Conf AIDS 9 (1993): 361
  9. Jacobson MA "Review of the toxicities of foscarnet." J Acquir Immune Defic Syndr 5 (1992): s11-7
  10. Aweeka FT, Omachi R, Jacobson MA, Schoenfeld P, Munley SM, Gambetoglio J "Pharmacokinetics (PK) of foscarnet in patients (PTS) with varying degrees of renal function." Int Conf AIDS 9 (1993): p485o-b26-2097
  11. Deray G, Katlama C, Dohin E "Prevention of foscarnet nephrotoxicity." Ann Intern Med 113 (1990): 332
  12. Ringden O, Lonnqvist B, Paulin T, et al "Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients." J Antimicrob Chemother 17 (1986): 373-87
  13. Farese RV Jr, Schambelan M, Hollander H, et al "Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis." Ann Intern Med 112 (1990): 955-6
  14. Deray G, Le Hoang P, Soubrie C, et al "Foscarnet-induced acute renal failure and effectiveness of haemodialysis." Lancet 2 (1987): 216
  15. "Product Information. Foscavir (foscarnet)." Astra USA, Westborough, MA.
  16. Deray G, Martinez F, Katlama C, et al "Foscarnet nephrotoxicity: mechanism, incidence and prevention." Am J Nephrol 9 (1989): 316-21
View all 16 references
Moderate

Foscarnet (Includes Foscavir) ↔ Hematologic Toxicities

Moderate Potential Hazard, High plausibility

Applies to: Anemia, Neutropenia, Thrombocytopenia

The use of foscarnet is associated with hematologic toxicities, most commonly anemia and granulocytopenia. Thrombocytopenia has been reported rarely. Therapy with foscarnet should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression. Routine blood counts are recommended.

References

  1. Ringden O, Lonnqvist B, Paulin T, et al "Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients." J Antimicrob Chemother 17 (1986): 373-87
  2. Willocks L, Brettle R "Foscarnet and pancytopenia." J Antimicrob Chemother 29 (1992): 232
  3. Jacobson MA "Review of the toxicities of foscarnet." J Acquir Immune Defic Syndr 5 (1992): s11-7
  4. "Product Information. Foscavir (foscarnet)." Astra USA, Westborough, MA.
  5. Palestine AG, Polis MA, De Smet MD, et al "A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS." Ann Intern Med 115 (1991): 665-73
  6. Chrisp P, Clissold SP "Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis." Drugs 41 (1991): 104-29
View all 6 references

Foscavir (foscarnet) drug Interactions

There are 170 drug interactions with Foscavir (foscarnet)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide